The US Food and Drug Administration (FDA) has granted approval for Sagent Pharmaceuticals’ bupivacaine hydrochloride injection.

The drug is indicated for the production of local or regional anaesthesia or analgaesia for dental and oral surgery procedures, diagnostic and therapeutic procedures, and obstetrical procedures.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Developed by Strides Arcolab, the injection will be available in six single-dose and two multi-dose latex-free vials.

Strides is responsible for developing and supplying injectable products that Sagent will market in the US.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact